{
  "Country": "NL",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "Sotorasib 960 mg orally once daily.",
      "Comparator": "Docetaxel.",
      "Outcomes": "May result in little to no difference in overall survival, objective response rate, and adverse events compared to docetaxel; potential increase in progression-free survival."
    }
  ],
  "SourceType": "clinical_guideline"
}